Purpose: This study was designed to identify genes that could predict response to
doxorubicin-based primary chemotherapy in breast cancer patients. Experimental Design …

Up to date clinical tests for predicting cancer chemotherapy response are not available and
individual markers have shown little predictive value. We hypothesized that gene expression …

Background A major challenge in oncology is the selection of the most effective
chemotherapeutic agents for individual patients, while the administration of ineffective …

Background Our goal was to identify gene signatures predictive of response to preoperative
systemic chemotherapy (PST) with epirubicin/cyclophosphamide (EC) in patients with …

Summary cDNA microarray analysis is a highly useful tool for the classification of tumors and
for prediction of patient prognosis to specific cancers based on this classification. However …

Summary Introduction Doxorubicin and cyclophosphamide (Adriamycin/cytoxan, AC) is a
standard chemotherapy regimen for breast cancer, but de novo resistance is frequent. We …

The goal of this study was to develop pharmacogenomic predictors in response to standard
chemotherapy drugs in breast cancer cell lines and test their predictive value in patients who …

Background Distant recurrences after antineoplastic treatment remain a serious problem for
breast cancer clinical management, which threats patients' life. Systemic therapy is …

Purpose We developed a multigene predictor of pathologic complete response (pCR) to
preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) …

For several decades, measurements from tumor tissue biomarkers have been used to
identify subsets of breast cancer patients that may benefit from specific therapies. Since the …